p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV-Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model.

Acute HEV in immunocompetent hosts is usually self-limiting and requires only supportive care; routine antiviral therapy is not indicated. EASL notes that ribavirin (typically a ~3-month course) may be considered in severe acute hepatitis E or acute-on-chronic liver failure. Chronic HEV, defined by EASL as HEV RNA persistence for more than 3 months (essentially confined to immunosuppressed patients, chiefly solid-organ transplant recipients, and predominantly genotype 3), is managed first by reducing immunosuppression where feasible, preferentially agents targeting T cells (this alone clears the virus in roughly a third of transplant recipients). If viremia persists, ribavirin monotherapy is first-line for at least 3 months (12 weeks); the ~600 mg/day figure is a study-derived median starting dose (from the pivotal retrospective transplant cohort), not a fixed standard, and the dose must be individualized, ribavirin is renally cleared and accumulates in renal impairment, so it is reduced according to creatinine clearance/eGFR, and it is adapted to hematologic tolerance, with hemoglobin monitored routinely for dose-dependent hemolytic anemia and the dose reduced as needed (adding epoetin and/or blood transfusion if the dose cannot be lowered further); at the end of therapy HEV RNA should be assessed in BOTH serum and stool, and treatment extended (e.g., to 6 months) if RNA remains detectable, particularly in stool, with sustained virological response defined as undetectable HEV RNA 12 weeks after stopping. Pegylated interferon-alfa is an alternative for ribavirin failures but is contraindicated in kidney, heart, lung and pancreas transplant recipients because of rejection risk; it may be considered in LIVER transplant recipients who fail ribavirin and in non-transplant immunosuppressed patients (e.g., HIV or haematological disease). Severe/fulminant HEV, notably genotype 1 (and 2) infection acquired in the second/third trimester of pregnancy, where acute liver failure with high maternal and fetal mortality is frequent, is managed in a specialist/ICU liver-failure setting with emergency liver-transplant evaluation; ribavirin is teratogenic and contraindicated in pregnancy (used only anecdotally in the third trimester in otherwise-fatal cases).